CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
作者： J Chu , Y Deng , D M Benson , S He , T Hughes
DOI: 10.1038/LEU.2013.279
关键词: Janus kinase 3 、 Lymphokine-activated killer cell 、 Cancer research 、 Biology 、 Interleukin 21 、 Immune system 、 Interleukin 12 、 CD40 、 Adoptive cell transfer 、 Natural killer T cell 、 Immunology
摘要: … of T cells or NK cells with chimeric antigen receptors (CARs) that directly target tumor-associated antigens. In fact, CAR T … All animal work was approved by The Ohio State University …
nature.com
sci-hub.se 参考文章(58)
G Tricot, DH Vesole, S Jagannath, J Hilton, N Munshi, B Barlogie, Graft-versus-myeloma effect: proof of principle Blood. ,vol. 87, pp. 1196- 1198 ,(1996) , 10.1182/BLOOD.V87.3.1196.BLOODJOURNAL8731196
Dana Chace, Karen L. Donaldson, Alan F. Wahl, Joseph A. Francisco, Clay B. Siegall, Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Research. ,vol. 60, pp. 3225- 3231 ,(2000)
Y. Laâbi, M.P. Gras, F. Carbonnel, J.C. Brouet, R. Berger, C.J. Larsen, A. Tsapis, A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. The EMBO Journal. ,vol. 11, pp. 3897- 3904 ,(1992) , 10.1002/J.1460-2075.1992.TB05482.X
Konrad Krzewski, John E. Coligan, Human NK cell lytic granules and regulation of their exocytosis Frontiers in Immunology. ,vol. 3, pp. 335- 335 ,(2012) , 10.3389/FIMMU.2012.00335
Torsten Tonn, Sven Becker, Ruth Esser, Dirk Schwabe, Erhard Seifried, Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. Journal of Hematotherapy & Stem Cell Research. ,vol. 10, pp. 535- 544 ,(2001) , 10.1089/15258160152509145
Francisco Borrego, José Peña, Rafael Solana, Regulation of CD69 expression on human natural killer cells: differential involvement of protein kinase C and protein tyrosine kinases European Journal of Immunology. ,vol. 23, pp. 1039- 1043 ,(1993) , 10.1002/EJI.1830230509
A Palumbo, S V Rajkumar, Treatment of newly diagnosed myeloma Leukemia. ,vol. 23, pp. 449- 456 ,(2009) , 10.1038/LEU.2008.325
Janelle A. Olson, Dennis B. Leveson-Gower, Saar Gill, Jeanette Baker, Andreas Beilhack, Robert S. Negrin, NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects Blood. ,vol. 115, pp. 4293- 4301 ,(2010) , 10.1182/BLOOD-2009-05-222190
G Maki, G M Hayes, A Naji, T Tyler, E D Carosella, N Rouas-Freiss, S A Gregory, NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients : implication of HLA-G Leukemia. ,vol. 22, pp. 998- 1006 ,(2008) , 10.1038/LEU.2008.15
Don M. Benson, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, Pascale Andre, Yvonne Efebera, Jérôme Tiollier, Michael A. Caligiuri, Sherif S. Farag, A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. ,vol. 120, pp. 4324- 4333 ,(2012) , 10.1182/BLOOD-2012-06-438028